118 related articles for article (PubMed ID: 8584685)
21. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
22. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.
Hirose A; Kato T; Ohno Y; Shimizu H; Tanaka H; Nakamura M; Katsube J
Jpn J Pharmacol; 1990 Jul; 53(3):321-9. PubMed ID: 1975278
[TBL] [Abstract][Full Text] [Related]
24. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis.
Tadokoro S; Okamura N; Sekine Y; Kanahara N; Hashimoto K; Iyo M
Schizophr Bull; 2012 Sep; 38(5):1012-20. PubMed ID: 21402722
[TBL] [Abstract][Full Text] [Related]
25. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
Florijn WJ; Tarazi FI; Creese I
J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
[TBL] [Abstract][Full Text] [Related]
26. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum.
Ishikane T; Kusumi I; Matsubara R; Matsubara S; Koyama T
Eur J Pharmacol; 1997 Feb; 321(2):163-9. PubMed ID: 9063684
[TBL] [Abstract][Full Text] [Related]
27. Binding profile of SM-9018, a novel antipsychotic candidate.
Kato T; Hirose A; Ohno Y; Shimizu H; Tanaka H; Nakamura M
Jpn J Pharmacol; 1990 Dec; 54(4):478-81. PubMed ID: 1982326
[TBL] [Abstract][Full Text] [Related]
28. Effects of atypical antipsychotic agents on social behavior in rodents.
Corbett R; Hartman H; Kerman LL; Woods AT; Strupczewski JT; Helsley GC; Conway PC; Dunn RW
Pharmacol Biochem Behav; 1993 May; 45(1):9-17. PubMed ID: 7685916
[TBL] [Abstract][Full Text] [Related]
29. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Huang M; Panos JJ; Kwon S; Oyamada Y; Rajagopal L; Meltzer HY
J Neurochem; 2014 Mar; 128(6):938-49. PubMed ID: 24164459
[TBL] [Abstract][Full Text] [Related]
30. Central 5-HT(4) receptors and dopamine-dependent motor behaviors: searching for a functional role.
De Deurwaerdère P; Cervo L; Stinus L; Spampinato U
Pharmacol Biochem Behav; 2002 Apr; 71(4):627-33. PubMed ID: 11888554
[TBL] [Abstract][Full Text] [Related]
31. Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT.
Dekeyne A; Rivet JM; Gobert A; Millan MJ
Neuropharmacology; 2001 Jun; 40(7):899-910. PubMed ID: 11378160
[TBL] [Abstract][Full Text] [Related]
32. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
33. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats.
Maruoka Y; Ohno Y; Kato T; Hirose A; Tatsuno T; Nakamura M
Jpn J Pharmacol; 1993 Aug; 62(4):419-22. PubMed ID: 7901446
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
35. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
36. Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds.
Ishizumi K; Kojima A; Antoku F; Saji I; Yoshigi M
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2139-51. PubMed ID: 8582016
[TBL] [Abstract][Full Text] [Related]
37. 5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity.
Charron A; Hage CE; Servonnet A; Samaha AN
Eur Neuropsychopharmacol; 2015 Dec; 25(12):2381-93. PubMed ID: 26508706
[TBL] [Abstract][Full Text] [Related]
38. DR4004, a putative 5-HT(7) receptor antagonist, also has functional activity at the dopamine D2 receptor.
Kogan HA; Marsden CA; Fone KC
Eur J Pharmacol; 2002 Aug; 449(1-2):105-11. PubMed ID: 12163113
[TBL] [Abstract][Full Text] [Related]
39. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Marin C; Parashos SA; Kapitzoglou-Logothetis V; Peppe A; Chase TN
Pharmacol Biochem Behav; 1993 May; 45(1):195-200. PubMed ID: 8516358
[TBL] [Abstract][Full Text] [Related]
40. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
